Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss
07:37am, Friday, 16'th Jan 2026
Britain's regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.
Novo shares jump 7% ahead of US prescription data for Wegovy pill
06:50am, Friday, 16'th Jan 2026
Shares of Novo Nordisk rose 7% on Friday, touching their highest level since September, and were among the top gainers in Europe, ahead of U.S. prescription data expected from analysts on the Danish d
Novo Nordisk Foundation Commits Up to $860 Million to European Innovation Push
11:50am, Thursday, 15'th Jan 2026
The Novo Nordisk Foundation, which controls Novo Nordisk A/S (NVO), is preparing to make the largest donation in its history, committing a grant of up to 5.5 bi
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
11:07am, Thursday, 15'th Jan 2026
Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.
Novo Nordisk obesity pill unlikely to impress early, UBS warns
09:21am, Thursday, 15'th Jan 2026
Novo Nordisk (NYSE:NVO) long-awaited obesity pill is unlikely to deliver clear early signals on demand, UBS has warned, even as the Swiss bank raised its price target on the Danish drugmaker's shares
Novo Nordisk obesity pill unlikely to impress early, UBS warns
09:15am, Thursday, 15'th Jan 2026
Novo Nordisk (NYSE:NVO) long-awaited obesity pill is unlikely to deliver clear early signals on demand, UBS has warned, even as the Swiss bank raised its...
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
06:46pm, Wednesday, 14'th Jan 2026
Novo Nordisk (NVO) concluded the recent trading session at $58.98, signifying a -1.12% move from its prior day's close.
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
12:08pm, Wednesday, 14'th Jan 2026
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the comp
Market Today: Boeing tops Airbus; Alphabet hits $4T
05:34pm, Tuesday, 13'th Jan 2026
Guru Stock PicksLarry Robbins has made the following transactions:Add in MYGN by 7.71%Stock News Trump floats 10% cap on card APRs: President Trump proposed a o
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:35pm, Tuesday, 13'th Jan 2026
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novo Nordisk flags near-term headwinds in international markets
01:54pm, Tuesday, 13'th Jan 2026
Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as competition intensifies after losing market exclusivity in several countries.
S&P 500, Nasdaq Turn Lower on Big Bank Burnout
12:01pm, Tuesday, 13'th Jan 2026
Even the S&P 500 Index (SPX) has slipped into the red, despite attempting early morning gains
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
11:01am, Tuesday, 13'th Jan 2026
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?
10:15am, Tuesday, 13'th Jan 2026
Eli Lilly and Novo Nordisk make the world's most popular weight loss drugs. These injectable products have generated double-digit growth, with revenue reaching blockbuster levels.
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?
08:42am, Tuesday, 13'th Jan 2026
The gap may be too hard to close in the next 12 months.
